A 1998 case report claimed mastic gum 'kills' H. pylori, and the supplement industry never let it go. Here's what the follow-up trials actually found — and where mastic gum's evidence is genuinely strong.
Mastic gum is the resin of *Pistacia lentiscus*, a shrub-like tree grown almost exclusively on the Greek island of Chios. It has been chewed and used medicinally for over 2,500 years, but its modern popularity traces to a single, widely misquoted 1998 letter in the *New England Journal of Medicine*. The headline claim — that mastic gum "kills" the ulcer-causing bacterium *Helicobacter pylori* — is still repeated across the supplement industry today. The actual evidence is more complicated, and more interesting, than that headline suggests.
Huwez and colleagues published a brief communication in NEJM in 1998 reporting that a small dose of mastic gum (1 gram daily for two weeks) resolved symptoms and, in a handful of patients, appeared to eliminate *H. pylori* on follow-up testing. The finding was based on a tiny, uncontrolled case series — not the kind of evidence that should drive clinical practice, but it was catchy enough to generate global headlines and a supplement gold rush.
Subsequent, better-controlled research did not replicate the original eradication claim. A widely cited *in vivo* study (Bebb et al., *Journal of Antimicrobial Chemotherapy*, 2003) treated confirmed *H. pylori*-positive patients with mastic gum and found no measurable reduction in bacterial load — a direct contradiction of the original report. Laboratory (in vitro) studies have shown mastic gum extract can inhibit *H. pylori* growth in a petri dish at concentrations far higher than what oral supplementation delivers to the stomach lining, which likely explains the gap between test-tube results and real-world eradication rates.
The honest current position, reflected in gastroenterology reviews, is that mastic gum is not a validated monotherapy for H. pylori eradication and should not replace standard triple or quadruple antibiotic therapy in a confirmed infection. Where it may still have a role is as an adjunct — some smaller trials combining mastic gum with standard eradication regimens have reported modestly improved outcomes and reduced GI side effects from the antibiotics themselves, though this use case needs larger confirmatory trials before it can be called established.
This is the part of the mastic gum story that gets less attention but has the best data behind it. A randomized, double-blind, placebo-controlled trial (Dabos et al., *Journal of Ethnopharmacology*, 2010) gave adults with functional dyspepsia (chronic upper-abdominal discomfort with no identifiable structural cause) either mastic gum or placebo for three weeks. The mastic gum group showed a statistically significant reduction in dyspepsia symptom scores compared to placebo — one of the cleaner human RCTs in the natural-supplement space for this specific complaint.